FTC Supports Federal DTC Ad Inquiry

Share this content:
The Federal Trade Commission is supporting efforts by the Food and Drug Administration to survey patients and doctors to determine the effects of direct-to-consumer pharmaceutical advertising.


FDA officials are trying to determine the potential benefits and harms caused by DTC ads. In comments submitted Thursday to the U.S. Office of Management and Budget, the FTC proposed additional inquiries into DTC effects on insurance and drug costs.


Such surveys could help officials evaluate whether DTC ads lead to lower prescription drug prices, the FTC said.


In June, the American Medical Association called for increased disclosures in DTC drug ads due to fears that the ads drive up drug prices by convincing consumers to request brand-name drugs when cheaper generics suffice.


Pharmaceutical Research and Manufacturers of America has stated that DTC drug ads empower consumers by helping them make their own healthcare choices.


Sign up to our newsletters

Company of the Week

Brightcove is the world's leading video platform. The most innovative and respected brands confidently rely on Brightcove to solve their most demanding communication challenges because of the unmatched performance and flexibility of our platform, our global scale and reliability, and our award-winning service. With thousands of customers and an industry-leading suite of cloud video products, Brightcove enables customers to drive compelling business results.

Find out more here »

Career Center

Check out hundreds of exciting professional opportunities available on DMN's Career Center.  
Explore careers in digital marketing, sales, eCommerce, marketing communications, IT, data strategies, and much more. And don't forget to update your resume so employers can contact you privately about job opportunities.

>>Click Here

Relive the 2017 Marketing Hall of Femme

Click the image above